Analyst Reco. Humacyte, Inc.

Equities

HUMA

US44486Q1031

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
7.48 ^USD	-17.80%		+4.62%	+163.38%

May. 30	Certain Common Stock of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	CI
May. 30	Certain Warrants of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Adjusts Price Target on Humacyte to $4 From $3, Maintains Neutral Rating	Mar. 08	MT
HC Wainwright Initiates Humacyte With Buy Rating, Price Target is $6	Dec. 11	MT
Humacyte, Inc. Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel	23-08-03	CI
Cantor Fitzgerald Initiates Humacyte at Overweight Rating With $6 Price Target	23-06-22	MT
BTIG Adjusts Humacyte's Price Target to $10 from $12, Keeps Buy Rating	22-07-18	MT
Piper Sandler Double Downgrades Humacyte to Underweight From Overweight, Adjusts Price Target to $4 From $10	22-05-16	MT
Cowen Starts Humacyte at Outperform With $17 Price Target	21-10-29	MT
HUMACYTE : Oppenheimer Starts Humacyte at Outperform with $16 Price Target	21-09-24	MT
HUMACYTE : BTIG Starts Humacyte at Buy with $19 Price Target	21-09-22	MT
HUMACYTE : Piper Sandler Starts Humacyte at Overweight With $17 Price Target	21-09-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer